Brown E Sherwood, Gorman April R, Hynan Linda S
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390-8849, USA.
J Clin Psychopharmacol. 2007 Oct;27(5):498-502. doi: 10.1097/JCP.0b013e31814db4c4.
Bipolar disorder is associated with the highest rates of substance abuse of any psychiatric disorder. Cocaine use is particularly common in patients with bipolar disorder. Both cocaine use and bipolar disorder are associated with mood symptoms and cognitive impairment. Therefore, treatments that stabilize mood, improve cognition, and reduce cocaine use would be useful. Citicoline modulates phospholipids metabolism and neurotransmitter levels and appears to improve cognition in some central nervous system disorders. A 12-week, randomized, placebo-controlled, parallel-group, add-on, proof-of-concept trial of citicoline was conducted in 44 outpatients with a history of mania or hypomania and cocaine dependence. The primary aim was to examine memory, but mood and cocaine use were also assessed.
Participants were evaluated with a structured diagnostic interview; Inventory of Depressive Symptomatology-Self-Report, Young Mania Rating Scale, and Rey Auditory Verbal Learning Test. Cocaine use was assessed with urine drug screens. Data were analyzed using mixed-model analysis of covariance, generalized estimating equations, and logistic regression analyses that used all of the available data.
A significant group effect (P = 0.006) favoring citicoline was observed on the Rey Auditory Verbal Learning Test alternative word list. No significant between-group differences were found on the Inventory of Depressive Symptomatology-Self-Report or Young Mania Rating Scale. The citicoline group had a significantly lower probability of a cocaine-positive urine at exit (P = 0.026). The covariate-adjusted odds ratio estimate was 6.41, suggesting that those who took placebo had 6.41-times higher odds of testing positive for cocaine at exit than those who took citicoline. Citicoline was well tolerated, with no participants to our knowledge discontinuing because of medication side effects.
The use of citicoline was associated with improvement relative to placebo in some aspects of declarative memory and cocaine use, but not mood. The findings are promising and suggest that larger trials of citicoline are warranted.
双相情感障碍与所有精神疾病中最高的物质滥用率相关。可卡因使用在双相情感障碍患者中尤为常见。可卡因使用和双相情感障碍均与情绪症状和认知障碍有关。因此,稳定情绪、改善认知并减少可卡因使用的治疗方法将是有益的。胞磷胆碱可调节磷脂代谢和神经递质水平,并且似乎能改善某些中枢神经系统疾病中的认知。对44名有躁狂或轻躁狂病史及可卡因依赖的门诊患者进行了一项为期12周的、随机、安慰剂对照、平行组、附加的胞磷胆碱概念验证试验。主要目的是检查记忆力,但也对情绪和可卡因使用情况进行了评估。
通过结构化诊断访谈、抑郁症状自评量表、杨氏躁狂评定量表和雷伊听觉词语学习测验对参与者进行评估。通过尿液药物筛查评估可卡因使用情况。使用混合模型协方差分析、广义估计方程以及使用所有可用数据的逻辑回归分析对数据进行分析。
在雷伊听觉词语学习测验的替代词表上观察到有利于胞磷胆碱的显著组效应(P = 0.006)。在抑郁症状自评量表或杨氏躁狂评定量表上未发现显著的组间差异。胞磷胆碱组在试验结束时尿液可卡因呈阳性的概率显著更低(P = 0.026)。协变量调整后的优势比估计值为6.41,这表明服用安慰剂的人在试验结束时可卡因检测呈阳性的几率比服用胞磷胆碱的人高6.41倍。胞磷胆碱耐受性良好,据我们所知,没有参与者因药物副作用而停药。
与安慰剂相比,胞磷胆碱的使用在陈述性记忆和可卡因使用的某些方面有所改善,但对情绪没有影响。这些发现很有前景,表明有必要对胞磷胆碱进行更大规模的试验。